Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14787175 | 0.89 | MDM4 (0.48) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL17446831 | 0.88 | MDM4 (0.46) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL14787476 | 0.88 | KMT2A (0.51) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL30554761 | 0.88 | KMT2A (0.51) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL18257462 | 0.85 | MDM4 (0.45) | MDM4TP53TLR2CASP3 | |
| SCHEMBL18257466 | 0.85 | MDM4 (0.45) | MDM4TP53TLR2CASP3 | |
| SCHEMBL21510639 | 0.84 | TLR2 (0.51) | KMT2ATLR2 | |
| SCHEMBL17815268 | 0.83 | TLR2 (0.52) | TLR2FDFT1 | |
| SCHEMBL13993335 | 0.83 | KMT2A (0.58) | KMT2ACASP3 | |
| SCHEMBL17446719 | 0.82 | PTPN1 (0.48) | KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340391-A1 | Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340391-A1 | Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions | CD274, PDCD1, PDCD1LG2 | KMT2A 2643/4885MDM4 550/4885TP53 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.